Parabilis Medicines closed a $305 million Series F to accelerate zolucatetide and other Helicon‑platform candidates that target intracellular, historically intractable oncology proteins. The financing, led by RA Capital, Fidelity and Janus Henderson, ups Parabilis’ valuation and funds late‑stage development and potential commercial preparations. The company said preliminary Phase 1/2 data for its lead candidate look compelling and that the Helicon peptide technology enables intracellular engagement of beta‑catenin and related pathways. Parabilis positioned the round as a step toward a potential IPO path, aligning with renewed investor interest in biotech platforms that address previously undruggable biology.